Although Xymedon did not suppress tumor growth in combination with doxorubicin, it significantly enhanced tumor necrosis and promoted intratumoral infiltration of CD3+, CD8+, and CD20+ lymphocytes, which correlated with improved immune surveillance. Here, CD8A is linked to neoplasm.